In the guideline for treating patients with psoriatic arthritis (PsA), the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) review a number of therapeutic options for the treatment of PsA , including oral small molecule (OSM), tumor necrosis factor inhibitor (TNFi), a Janus kinase (JAK) inhibitor and interleukin inhibitor therapeutic agents. Which of the following does the ACR recommend for first-line therapy for patients with PsA?
Better luck next time
Nice job!